

**Johnson&Johnson**  
**Third Quarter 2025**  
**Other Financial Disclosures**  
**Table of Contents**

<u><a href="#">Table 1: Sales by Segment</a></u>	1
<u><a href="#">Table 2: Sales by Geographic Area</a></u>	2
<u><a href="#">Table 3: Sales of Key Products/Franchises</a></u>	3 - 7
<u><a href="#">Table 4: Condensed Consolidated Statement of Earnings - QTD</a></u>	8
<u><a href="#">Table 5: Condensed Consolidated Statement of Earnings - YTD</a></u>	9
<u><a href="#">Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD</a></u>	10
<u><a href="#">Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD</a></u>	11
<u><a href="#">Table 8: Non-GAAP Adjusted Net Earnings</a></u>	12
<u><a href="#">Table 9: Non-GAAP P&amp;L by Segment Reconciliation 2025 - QTD</a></u>	13
<u><a href="#">Table 10: Non-GAAP P&amp;L by Segment Reconciliation 2024 - QTD</a></u>	14
<u><a href="#">Table 11: Non-GAAP P&amp;L by Segment Reconciliation 2025 - YTD</a></u>	15
<u><a href="#">Table 12: Non-GAAP P&amp;L by Segment Reconciliation 2024 - YTD</a></u>	16

**Johnson & Johnson and Subsidiaries**
**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

**THIRD QUARTER**

	2025	2024	Total	Percent Change	
				Operations	Currency
<b>Sales to customers by segment of business</b>					
Innovative Medicine					
U.S.	\$ 9,402	8,871	6.0 %	6.0	-
International	6,161	5,709	7.9	4.3	3.6
	<b>15,563</b>	<b>14,580</b>	<b>6.8</b>	<b>5.3</b>	<b>1.5</b>
MedTech					
U.S.	4,306	4,038	6.6	6.6	-
International	4,124	3,853	7.0	4.5	2.5
	<b>8,430</b>	<b>7,891</b>	<b>6.8</b>	<b>5.6</b>	<b>1.2</b>
U.S.	13,708	12,909	6.2	6.2	-
International	10,285	9,562	7.6	4.4	3.2
Worldwide	<b>\$ 23,993</b>	<b>22,471</b>	<b>6.8 %</b>	<b>5.4</b>	<b>1.4</b>

**NINE MONTHS**

	2025	2024	Total	Percent Change	
				Operations	Currency
<b>Sales to customers by segment of business</b>					
Innovative Medicine					
U.S.	\$ 26,655	24,993	6.7 %	6.7	-
International	17,983	17,639	1.9	1.3	0.6
	<b>44,638</b>	<b>42,632</b>	<b>4.7</b>	<b>4.5</b>	<b>0.2</b>
MedTech					
U.S.	12,902	12,105	6.6	6.6	-
International	12,089	11,564	4.5	3.9	0.6
	<b>24,991</b>	<b>23,669</b>	<b>5.6</b>	<b>5.3</b>	<b>0.3</b>
U.S.	39,557	37,098	6.6	6.6	-
International	30,072	29,203	3.0	2.3	0.7
Worldwide	<b>\$ 69,629</b>	<b>66,301</b>	<b>5.0 %</b>	<b>4.7</b>	<b>0.3</b>

**Note:** Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

**Johnson & Johnson and Subsidiaries**
**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

	THIRD QUARTER				
	Percent Change				
	2025	2024	Total	Operations	Currency
<b>Sales to customers by geographic area</b>					
U.S.	\$ 13,708	12,909	6.2 %	6.2	-
Europe	5,440	4,914	10.7	4.4	6.3
Western Hemisphere excluding U.S.	1,231	1,173	4.9	7.3	(2.4)
Asia-Pacific, Africa	3,614	3,475	4.0	3.4	0.6
International	10,285	9,562	7.6	4.4	3.2
Worldwide	\$ 23,993	22,471	6.8 %	5.4	1.4

**NINE MONTHS**

	NINE MONTHS				
	Percent Change				
	2025	2024	Total	Operations	Currency
<b>Sales to customers by geographic area</b>					
U.S.	\$ 39,557	37,098	6.6 %	6.6	-
Europe	15,937	15,291	4.2	1.5	2.7
Western Hemisphere excluding U.S.	3,604	3,579	0.7	7.6	(6.9)
Asia-Pacific, Africa	10,531	10,333	1.9	1.8	0.1
International	30,072	29,203	3.0	2.3	0.7
Worldwide	\$ 69,629	66,301	5.0 %	4.7	0.3

**Note:** Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

INNOVATIVE MEDICINE SEGMENT <sup>(2)</sup>	REPORTED SALES vs. PRIOR PERIOD (\$MM)						
	THIRD QUARTER						
			% Change				
	2025	2024	Reported	Operational <sup>(1)</sup>	Currency		
<b>ONCOLOGY</b>							
US	\$ 3,468	2,816	23.2%	23.2%	-		
Intl	3,060	2,565	19.3%	14.8%	4.5%		
WW	6,529	5,380	21.3%	19.2%	2.1%		
<b>CARVYKTI</b>							
US	396	258	53.3%	53.3%	-		
Intl	128	27	*	*	*		
WW	524	286	83.5%	81.4%	2.1%		
<b>DARZALEX</b>							
US	2,088	1,684	24.0%	24.0%	-		
Intl	1,584	1,332	18.9%	14.7%	4.2%		
WW	3,672	3,016	21.7%	19.9%	1.8%		
<b>ERLEADA</b>							
US	378	337	12.3%	12.3%	-		
Intl	558	453	23.0%	17.6%	5.4%		
WW	936	790	18.4%	15.3%	3.1%		
<b>IMBRUVICA</b>							
US	211	259	(18.3)%	(18.3)%	-		
Intl	483	494	(2.3)%	(6.6)%	4.3%		
WW	695	753	(7.8)%	(10.6)%	2.8%		
<b>RYBREVANT / LAZCLUZE <sup>(3)</sup></b>							
US	136	68	99.7%	99.7%	-		
Intl	61	21	*	*	*		
WW	198	89	*	*	*		
<b>TALVEY</b>							
US	85	64	34.2%	34.2%	-		
Intl	37	12	*	*	*		
WW	122	75	60.8%	59.1%	1.7%		
<b>TECVAYLI</b>							
US	115	105	9.3%	9.3%	-		
Intl	62	30	*	*	*		
WW	177	135	31.3%	29.9%	1.4%		
<b>ZYTIGA / abiraterone acetate</b>							
US	5	5	(25.0)%	(25.0)%	-		
Intl	108	144	(25.1)%	(26.8)%	1.7%		
WW	113	150	(25.1)%	(26.8)%	1.7%		
<b>OTHER ONCOLOGY</b>							
US	56	36	54.6%	54.6%	-		
Intl	39	50	(22.2)%	(25.6)%	3.4%		
WW	94	86	9.7%	7.7%	2.0%		
REPORTED SALES vs. PRIOR PERIOD (\$MM)							
NINE MONTHS							
	2025	2024	Reported	Operational <sup>(1)</sup>	Currency		
<b>ONCOLOGY</b>							
US	\$ 9,866	7,835	25.9%	25.9%	-		
Intl	8,652	7,450	16.1%	15.0%	1.1%		
WW	18,519	15,284	21.2%	20.6%	0.6%		
<b>CARVYKTI</b>							
US	1,072	565	89.6%	89.6%	-		
Intl	260	63	*	*	*		
WW	1,332	629	*	*	*		
<b>DARZALEX</b>							
US	5,934	4,789	23.9%	23.9%	-		
Intl	4,514	3,797	18.9%	17.9%	1.0%		
WW	10,448	8,586	21.7%	21.3%	0.4%		
<b>ERLEADA</b>							
US	1,048	940	11.5%	11.5%	-		
Intl	1,567	1,275	22.9%	21.1%	1.8%		
WW	2,615	2,215	18.0%	17.0%	1.0%		
<b>IMBRUVICA</b>							
US	685	770	(11.0)%	(11.0)%	-		
Intl	1,453	1,537	(5.4)%	(6.4)%	1.0%		
WW	2,139	2,307	(7.3)%	(7.9)%	0.6%		
<b>RYBREVANT / LAZCLUZE <sup>(3)</sup></b>							
US	388	156	*	*	-		
Intl	130	49	*	*	*		
WW	518	205	*	*	*		
<b>TALVEY</b>							
US	235	173	35.8%	35.8%	-		
Intl	79	29	*	*	*		
WW	314	202	55.3%	54.9%	0.4%		
<b>TECVAYLI</b>							
US	334	310	7.5%	7.5%	-		
Intl	160	93	73.0%	72.6%	0.4%		
WW	494	403	22.6%	22.5%	0.1%		
<b>ZYTIGA / abiraterone acetate</b>							
US	18	25	(30.4)%	(30.4)%	-		
Intl	365	470	(22.3)%	(23.0)%	0.7%		
WW	383	496	(22.8)%	(23.4)%	0.6%		
<b>OTHER ONCOLOGY</b>							
US	153	106	44.8%	44.8%	-		
Intl	123	136	(9.7)%	(10.6)%	0.9%		
WW	276	242	14.0%	13.6%	0.4%		

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)						
	THIRD QUARTER					
	% Change					
	2025	2024	Reported	Operational <sup>(1)</sup>	Currency	
<b>IMMUNOLOGY</b>						
US	\$ 2,676	3,068	(12.8)%	(12.8)%	-	
Intl	1,493	1,552	(3.9)%	(6.3)%	2.4%	
WW	4,168	4,621	(9.8)%	(10.6)%	0.8%	
<b>REMICADE</b>						
US	326	281	16.2%	16.2%	-	
US Exports <sup>(4)</sup>	19	27	(30.9)%	(30.9)%	-	
Intl	132	112	17.7%	16.7%	1.0%	
WW	476	419	13.6%	13.3%	0.3%	
<b>SIMPONI / SIMPONI ARIA</b>						
US	309	299	3.6%	3.6%	-	
Intl	377	218	73.0%	69.8%	3.2%	
WW	687	516	32.9%	31.5%	1.4%	
<b>STELARA</b>						
US	1,022	1,770	(42.3)%	(42.3)%	-	
Intl	549	906	(39.4)%	(41.4)%	2.0%	
WW	1,570	2,676	(41.3)%	(42.0)%	0.7%	
<b>TREMFYA</b>						
US	989	691	43.1%	43.1%	-	
Intl	434	316	37.4%	33.4%	4.0%	
WW	1,424	1,007	41.3%	40.1%	1.2%	
<b>OTHER IMMUNOLOGY</b>						
US	12	1	*	*	-	
Intl	0	0	-	-	-	
WW	12	1	*	*	-	
<b>NEUROSCIENCE</b>						
US	1,367	1,094	25.0%	25.0%	-	
Intl	658	662	(0.7)%	(2.6)%	1.9%	
WW	2,024	1,755	15.3%	14.6%	0.7%	
<b>CAPLYTA <sup>(5)</sup></b>						
US	240	-	*	*	-	
Intl	-	-	-	-	-	
WW	240	-	*	*	-	
<b>CONCERTA / Methylphenidate</b>						
US	14	26	(49.2)%	(49.2)%	-	
Intl	127	117	9.0%	8.5%	0.5%	
WW	140	142	(1.4)%	(1.8)%	0.4%	
<b>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</b>						
US	664	780	(14.9)%	(14.9)%	-	
Intl	267	269	(0.9)%	(3.0)%	2.1%	
WW	929	1,049	(11.3)%	(11.9)%	0.6%	
<b>SPRAVATO</b>						
US	405	243	67.1%	67.1%	-	
Intl	53	42	28.9%	23.8%	5.1%	
WW	459	284	61.5%	60.8%	0.7%	
<b>OTHER NEUROSCIENCE</b>						
US	46	46	0.4%	0.4%	-	
Intl	210	235	(10.7)%	(12.3)%	1.6%	
WW	256	281	(8.9)%	(10.2)%	1.3%	
REPORTED SALES vs. PRIOR PERIOD (\$MM)						
	NINE MONTHS					
	% Change					
	2025	2024	Reported	Operational <sup>(1)</sup>	Currency	
	\$ 7,377	8,499	(13.2)%	(13.2)%	-	
	4,492	5,090	(11.8)%	(11.5)%	(0.3)%	
	11,868	13,590	(12.7)%	(12.6)%	(0.1)%	
	923	778	18.7%	18.7%	-	
	63	89	(29.6)%	(29.6)%	-	
	413	380	8.6%	10.4%	(1.8)%	
	1,398	1,246	12.2%	12.7%	(0.5)%	
	906	820	10.5%	10.5%	-	
	1,130	787	43.5%	44.6%	(1.1)%	
	2,036	1,607	26.7%	27.2%	(0.5)%	
	3,081	5,021	(38.6)%	(38.6)%	-	
	1,768	2,991	(40.9)%	(40.8)%	(0.1)%	
	4,848	8,012	(39.5)%	(39.5)%	0.0%	
	2,384	1,789	33.3%	33.3%	-	
	1,181	932	26.7%	26.1%	0.6%	
	3,566	2,721	31.0%	30.8%	0.2%	
	21	3	*	*	-	
	0	0	-	-	-	
	21	3	*	*	-	
	3,712	3,250	14.2%	14.2%	-	
	2,011	2,090	(3.8)%	(3.7)%	(0.1)%	
	5,722	5,340	7.2%	7.2%	0.0%	
	451	-	*	*	-	
	-	-	-	-	-	
	451	-	*	*	-	
	76	101	(24.9)%	(24.9)%	-	
	376	382	(1.4)%	(0.4)%	(1.0)%	
	452	482	(6.3)%	(5.5)%	(0.8)%	
	2,021	2,329	(13.2)%	(13.2)%	-	
	804	830	(3.1)%	(3.0)%	(0.1)%	
	2,824	3,159	(10.6)%	(10.5)%	(0.1)%	
	1,047	660	58.7%	58.7%	-	
	146	120	21.9%	21.4%	0.5%	
	1,193	780	53.0%	52.9%	0.1%	
	119	161	(26.4)%	(26.4)%	-	
	684	759	(9.8)%	(9.9)%	0.1%	
	803	920	(12.7)%	(12.8)%	0.1%	

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)						
THIRD QUARTER						
	% Change					
	2025	2024	Reported	Operational <sup>(1)</sup>	Currency	
<b>PULMONARY HYPERTENSION</b>						
US	\$ 815	815	(0.1)%	(0.1)%	-	
Intl	300	287	4.8%	2.0%	2.8%	
WW	1,115	1,102	1.1%	0.4%	0.7%	
<b>OPSUMIT / OPSYNVI</b>						
US	409	417	(1.6)%	(1.6)%	-	
Intl	168	166	1.1%	(1.8)%	2.9%	
WW	578	583	(0.8)%	(1.7)%	0.9%	
<b>UPTRAVI</b>						
US	392	379	3.5%	3.5%	-	
Intl	92	80	15.2%	12.0%	3.2%	
WW	484	458	5.6%	5.0%	0.6%	
<b>OTHER PULMONARY HYPERTENSION</b>						
US	13	21	(36.5)%	(36.5)%	-	
Intl	39	39	(1.0)%	(2.5)%	1.5%	
WW	53	60	(13.1)%	(14.1)%	1.0%	
<b>INFECTIOUS DISEASES</b>						
US	326	365	(10.5)%	(10.5)%	-	
Intl	501	471	6.4%	0.5%	5.9%	
WW	829	836	(0.9)%	(4.3)%	3.4%	
<b>EDURANT / rilpivirine</b>						
US	7	8	(7.9)%	(7.9)%	-	
Intl	378	323	16.9%	9.9%	7.0%	
WW	385	330	16.4%	9.5%	6.9%	
<b>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</b>						
US	315	355	(11.0)%	(11.0)%	-	
Intl	81	94	(13.6)%	(18.5)%	4.9%	
WW	397	449	(11.6)%	(12.6)%	1.0%	
<b>OTHER INFECTIOUS DISEASES</b>						
US	4	3	57.3%	57.3%	-	
Intl	42	54	(21.2)%	(22.3)%	1.1%	
WW	47	56	(17.5)%	(18.5)%	1.0%	
<b>CARDIOVASCULAR / METABOLISM / OTHER</b>						
US	750	713	5.3%	5.3%	-	
Intl	149	170	(13.1)%	(15.6)%	2.5%	
WW	899	884	1.7%	1.2%	0.5%	
<b>XARELTO</b>						
US	635	592	7.4%	7.4%	-	
Intl	-	-	-	-	-	
WW	635	592	7.4%	7.4%	-	
<b>OTHER</b>						
US	115	121	(5.2)%	(5.2)%	-	
Intl	149	170	(13.1)%	(15.6)%	2.5%	
WW	264	292	(9.8)%	(11.3)%	1.5%	
<b>TOTAL INNOVATIVE MEDICINE</b>						
US	9,402	8,871	6.0%	6.0%	-	
Intl	6,161	5,709	7.9%	4.3%	3.6%	
WW	\$ 15,563	14,580	6.8%	5.3%	1.5%	
REPORTED SALES vs. PRIOR PERIOD (\$MM)						
NINE MONTHS						
	% Change					
	2025	2024	Reported	Operational <sup>(1)</sup>	Currency	
US	\$ 2,358	2,324	1.5%	1.5%	-	
Intl	895	866	3.4%	2.6%	0.8%	
WW	3,253	3,190	2.0%	1.8%	0.2%	
<b>OPSUMIT / OPSYNVI</b>						
US	1,175	1,149	2.3%	2.3%	-	
Intl	507	506	0.2%	(0.7)%	0.9%	
WW	1,682	1,655	1.7%	1.4%	0.3%	
<b>UPTRAVI</b>						
US	1,139	1,120	1.7%	1.7%	-	
Intl	272	232	17.0%	16.4%	0.6%	
WW	1,411	1,352	4.3%	4.2%	0.1%	
<b>OTHER PULMONARY HYPERTENSION</b>						
US	44	56	(21.5)%	(21.5)%	-	
Intl	116	127	(8.9)%	(9.1)%	0.2%	
WW	160	183	(12.7)%	(12.9)%	0.2%	
<b>INFECTIOUS DISEASES</b>						
US	961	1,023	(6.0)%	(6.0)%	-	
Intl	1,472	1,599	(7.9)%	(9.8)%	1.9%	
WW	2,434	2,622	(7.2)%	(8.3)%	1.1%	
<b>EDURANT / rilpivirine</b>						
US	21	24	(11.8)%	(11.8)%	-	
Intl	1,082	926	16.8%	13.6%	3.2%	
WW	1,103	950	16.1%	13.0%	3.1%	
<b>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</b>						
US	932	990	(5.8)%	(5.8)%	-	
Intl	264	315	(16.1)%	(16.6)%	0.5%	
WW	1,196	1,305	(8.3)%	(8.4)%	0.1%	
<b>OTHER INFECTIOUS DISEASES</b>						
US	8	10	(11.0)%	(11.0)%	-	
Intl	126	358	(64.7)%	(64.6)%	(0.1)%	
WW	135	367	(63.3)%	(63.2)%	(0.1)%	
<b>CARDIOVASCULAR / METABOLISM / OTHER</b>						
US	2,381	2,061	15.5%	15.5%	-	
Intl	461	543	(15.2)%	(14.7)%	(0.5)%	
WW	2,842	2,605	9.1%	9.2%	(0.1)%	
<b>XARELTO</b>						
US	1,946	1,697	14.7%	14.7%	-	
Intl	-	-	-	-	-	
WW	1,946	1,697	14.7%	14.7%	-	
<b>OTHER</b>						
US	435	364	19.4%	19.4%	-	
Intl	461	543	(15.2)%	(14.7)%	(0.5)%	
WW	896	908	(1.3)%	(1.0)%	(0.3)%	
<b>TOTAL INNOVATIVE MEDICINE</b>						
US	26,655	24,993	6.7%	6.7%	-	
Intl	17,983	17,639	1.9%	1.3%	0.6%	
WW	\$ 44,638	42,632	4.7%	4.5%	0.2%	

See footnotes at end of schedule

MEDTECH SEGMENT <sup>(2)</sup>	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	THIRD QUARTER					NINE MONTHS				
			% Change					% Change		
	2025	2024	Reported	Operational <sup>(1)</sup>	Currency	2025	2024	Reported	Operational <sup>(1)</sup>	Currency
<b>CARDIOVASCULAR</b>										
US	\$ 1,306	1,148	13.8%	13.8%	-	\$ 3,931	3,292	19.4%	19.4%	-
Intl	908	819	10.8%	8.4%	2.4%	2,698	2,353	14.6%	13.8%	0.8%
WW	2,213	1,966	12.6%	11.6%	1.0%	6,629	5,645	17.4%	17.1%	0.3%
<b>ELECTROPHYSIOLOGY</b>										
US	720	660	9.1%	9.1%	-	2,145	2,057	4.3%	4.3%	-
Intl	698	619	12.6%	10.4%	2.2%	2,064	1,889	9.2%	8.6%	0.6%
WW	1,418	1,279	10.8%	9.7%	1.1%	4,209	3,946	6.7%	6.4%	0.3%
<b>ABIOMED</b>										
US	336	293	14.5%	14.5%	-	1,035	905	14.3%	14.3%	-
Intl	86	68	26.8%	20.2%	6.6%	256	207	23.9%	20.7%	3.2%
WW	423	362	16.8%	15.6%	1.2%	1,291	1,112	16.1%	15.5%	0.6%
<b>SHOCKWAVE<sup>(6)</sup></b>										
US	220	163	34.4%	34.4%	-	659	240	*	*	-
Intl	59	66	(11.2)%	(12.4)%	1.2%	169	66	*	*	*
WW	278	229	21.2%	20.9%	0.3%	828	306	*	*	*
<b>OTHER CARDIOVASCULAR</b>										
US	30	30	0.0%	0.0%	-	93	89	4.2%	4.2%	-
Intl	65	66	(1.0)%	(2.5)%	1.5%	209	192	9.0%	8.7%	0.3%
WW	95	96	(0.7)%	(1.7)%	1.0%	302	281	7.5%	7.2%	0.3%
<b>ORTHOPAEDICS</b>										
US	1,396	1,359	2.7%	2.7%	-	4,200	4,229	(0.7)%	(0.7)%	-
Intl	878	832	5.6%	1.9%	3.7%	2,620	2,614	0.3%	(1.1)%	1.4%
WW	2,274	2,191	3.8%	2.4%	1.4%	6,820	6,843	(0.3)%	(0.8)%	0.5%
<b>HIPS</b>										
US	262	250	4.7%	4.7%	-	796	785	1.3%	1.3%	-
Intl	144	131	9.7%	5.9%	3.8%	440	435	1.2%	0.0%	1.2%
WW	405	381	6.4%	5.1%	1.3%	1,235	1,220	1.3%	0.9%	0.4%
<b>KNEES</b>										
US	216	212	2.1%	2.1%	-	673	684	(1.5)%	(1.5)%	-
Intl	160	140	14.3%	10.9%	3.4%	482	463	4.0%	3.0%	1.0%
WW	377	352	7.0%	5.6%	1.4%	1,155	1,147	0.7%	0.3%	0.4%
<b>TRAUMA</b>										
US	512	497	3.0%	3.0%	-	1,515	1,499	1.1%	1.1%	-
Intl	281	265	6.4%	2.5%	3.9%	818	786	4.1%	2.7%	1.4%
WW	793	761	4.2%	2.9%	1.3%	2,333	2,285	2.1%	1.6%	0.5%
<b>SPINE, SPORTS &amp; OTHER</b>										
US	406	400	1.3%	1.3%	-	1,216	1,262	(3.7)%	(3.7)%	-
Intl	293	296	(1.1)%	(4.8)%	3.7%	881	930	(5.3)%	(6.8)%	1.5%
WW	698	696	0.3%	(1.3)%	1.6%	2,096	2,191	(4.3)%	(5.0)%	0.7%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)						REPORTED SALES vs. PRIOR PERIOD (\$MM)					
	THIRD QUARTER					NINE MONTHS					
			% Change					% Change			
	2025	2024	Reported	Operational <sup>(1)</sup>	Currency		2025	2024	Reported	Operational <sup>(1)</sup>	Currency
<b>SURGERY</b>											
US	\$ 1,031	983	4.9%	4.9%	-		\$ 3,076	2,965	3.8%	3.8%	-
Intl	1,511	1,451	4.1%	2.2%	1.9%		4,417	4,373	1.0%	0.9%	0.1%
WW	2,542	2,434	4.4%	3.3%	1.1%		7,493	7,338	2.1%	2.1%	0.0%
<b>ADVANCED</b>											
US	477	448	6.2%	6.2%	-		1,411	1,360	3.7%	3.7%	-
Intl	688	661	4.2%	2.1%	2.1%		1,991	1,977	0.7%	0.5%	0.2%
WW	1,165	1,109	5.0%	3.8%	1.2%		3,402	3,337	1.9%	1.8%	0.1%
<b>GENERAL</b>											
US	555	535	3.8%	3.8%	-		1,666	1,605	3.8%	3.8%	-
Intl	823	791	4.0%	2.2%	1.8%		2,426	2,397	1.2%	1.3%	(0.1)%
WW	1,378	1,325	3.9%	2.9%	1.0%		4,092	4,001	2.3%	2.3%	0.0%
<b>VISION</b>											
US	571	549	4.2%	4.2%	-		1,694	1,619	4.7%	4.7%	-
Intl	828	751	10.2%	7.5%	2.7%		2,354	2,224	5.8%	5.0%	0.8%
WW	1,400	1,300	7.7%	6.1%	1.6%		4,048	3,843	5.3%	4.8%	0.5%
<b>CONTACT LENSES / OTHER</b>											
US	456	441	3.5%	3.5%	-		1,337	1,288	3.8%	3.8%	-
Intl	562	527	6.6%	3.4%	3.2%		1,565	1,508	3.8%	2.4%	1.4%
WW	1,018	968	5.2%	3.5%	1.7%		2,902	2,796	3.8%	3.1%	0.7%
<b>SURGICAL</b>											
US	116	108	7.0%	7.0%	-		358	331	8.0%	8.0%	-
Intl	266	225	18.7%	17.1%	1.6%		789	717	10.1%	10.3%	(0.2)%
WW	383	333	14.9%	13.8%	1.1%		1,147	1,048	9.4%	9.6%	(0.2)%
<b>TOTAL MEDTECH</b>											
US	4,306	4,038	6.6%	6.6%	-		12,902	12,105	6.6%	6.6%	-
Intl	4,124	3,853	7.0%	4.5%	2.5%		12,089	11,564	4.5%	3.9%	0.6%
WW	\$ 8,430	7,891	6.8%	5.6%	1.2%		\$ 24,991	23,669	5.6%	5.3%	0.3%

**Note:** Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

\* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE

(4) Reported as U.S. sales

(5) Acquired with Intra-Cellular Therapies on April 2, 2025

(6) Due to the timing of the integration of the US and foreign affiliates in the year of acquisition (2024), prior quarter (Q3 2024) Shockwave International revenue includes ~\$20M of sales that should be reflected in the U.S. business. Year-to-date and total Shockwave sales are not impacted, and the amount was immaterial to recast prior year reporting.

## Johnson &amp; Johnson and Subsidiaries

## Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

THIRD QUARTER

	2025		2024		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 23,993	100.0	\$ 22,471	100.0	6.8
Cost of products sold	7,303	30.4	6,963	31.0	4.9
Gross Profit	16,690	69.6	15,508	69.0	7.6
Selling, marketing and administrative expenses	5,922	24.7	5,478	24.3	8.1
Research and development expense	3,672	15.3	4,952	22.0	(25.8)
Interest (income) expense, net	18	0.1	(99)	(0.4)	
Other (income) expense, net	(478)	(2.0)	1,798	8.0	
Restructuring	63	0.3	41	0.2	
Earnings before provision for taxes on income	7,493	31.2	3,338	14.9	124.5
Provision for taxes on income	2,341	9.7	644	2.9	263.5
Net earnings	\$ 5,152	21.5	\$ 2,694	12.0	91.2
Net earnings per share (Diluted)	\$ 2.12		\$ 1.11		91.0
Average shares outstanding (Diluted)	2,428.6		2,427.9		
Effective tax rate	31.2 %		19.3 %		
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	\$ 8,436	35.2	\$ 7,277	32.4	15.9
Net earnings	\$ 6,801	28.3	\$ 5,876	26.1	15.7
Net earnings per share (Diluted)	\$ 2.80		\$ 2.42		15.7
Effective tax rate	19.4 %		19.3 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

## Johnson &amp; Johnson and Subsidiaries

## Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

NINE MONTHS

	2025		2024		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 69,629	100.0	\$ 66,301	100.0	5.0
Cost of products sold	22,288	32.0	20,343	30.7	9.6
Gross Profit	47,341	68.0	45,958	69.3	3.0
Selling, marketing and administrative expenses	16,923	24.3	16,416	24.8	3.1
Research and development expense	10,413	15.0	11,934	18.0	(12.7)
In-process research and development impairments	-	-	194	0.3	
Interest (income) expense, net	(62)	(0.1)	(433)	(0.7)	
Other (income) expense, net	(7,692)	(11.1)	4,855	7.3	
Restructuring	144	0.2	192	0.3	
Earnings before provision for taxes on income	27,615	39.7	12,800	19.3	115.7
Provision for taxes on income	5,927	8.6	2,165	3.3	173.8
Net earnings	\$ 21,688	31.1	\$ 10,635	16.0	103.9
Net earnings per share (Diluted)	\$ 8.94		\$ 4.38		104.1
Average shares outstanding (Diluted)	2,424.8		2,429.5		
Effective tax rate	21.5 %		16.9 %		
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	\$ 24,635	35.4	\$ 23,558	35.5	4.6
Net earnings	\$ 20,206	29.0	\$ 19,296	29.1	4.7
Net earnings per share (Diluted)	\$ 8.33		\$ 7.94		4.9
Effective tax rate	18.0 %		18.1 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

**Johnson & Johnson and Subsidiaries**  
**Reconciliation of Non-GAAP Financial Measure**

**Adjusted Operational Sales Growth**  
**THIRD QUARTER 2025 ACTUAL vs. 2024 ACTUAL**

	Segments		
	<u>Innovative Medicine</u>		<u>MedTech</u>
	<b>WW As Reported</b>	<b>6.8%</b>	<b>6.8%</b>
U.S.	6.0%	6.6%	6.2%
International	7.9%	7.0%	7.6%
<b>WW Currency</b>	<b>1.5</b>	<b>1.2</b>	<b>1.4</b>
U.S.	-	-	-
International	3.6	2.5	3.2
<b>WW Operational</b>	<b>5.3%</b>	<b>5.6%</b>	<b>5.4%</b>
U.S.	6.0%	6.6%	6.2%
International	4.3%	4.5%	4.4%
<b>Caplyta</b>	<b>(1.6)</b>		<b>(1.1)</b>
U.S.	(2.7)		(1.9)
International	0.0		0.0
<b>All Other Acquisitions and Divestitures (A&amp;D)</b>	<b>0.0</b>	<b>0.1</b>	<b>0.1</b>
U.S.	0.0	0.2	0.1
International	0.0	0.1	0.0
<b>WW Adjusted Operational Ex A&amp;D</b>	<b>3.7%</b>	<b>5.7%</b>	<b>4.4%</b>
U.S.	3.3%	6.8%	4.4%
International	4.3%	4.6%	4.4%

**Note:** Percentages are based on actual, non-rounded figures and may not sum

**Johnson & Johnson and Subsidiaries**  
**Reconciliation of Non-GAAP Financial Measure**

**Adjusted Operational Sales Growth**  
**NINE MONTHS 2025 ACTUAL vs. 2024 ACTUAL**

<b>Segments</b>			
	<b>Innovative Medicine</b>	<b>MedTech</b>	<b>Total</b>
<b>WW As Reported</b>	<b>4.7%</b>	<b>5.6%</b>	<b>5.0%</b>
U.S.	6.7%	6.6%	6.6%
International	1.9%	4.5%	3.0%
<b>WW Currency</b>	<b>0.2</b>	<b>0.3</b>	<b>0.3</b>
U.S.	-	-	-
International	0.6	0.6	0.7
<b>WW Operational</b>	<b>4.5%</b>	<b>5.3%</b>	<b>4.7%</b>
U.S.	6.7%	6.6%	6.6%
International	1.3%	3.9%	2.3%
<b>Shockwave</b>		<b>(1.9)</b>	<b>(0.6)</b>
U.S.		(2.9)	(0.9)
International		(0.8)	(0.2)
<b>Caplyta</b>	<b>(1.1)</b>		<b>(0.7)</b>
U.S.	(1.8)		(1.2)
International	0.0		0.0
<b>All Other Acquisitions and Divestitures (A&amp;D)</b>	<b>0.0</b>	<b>0.3</b>	<b>0.1</b>
U.S.	0.0	0.4	0.1
International	0.1	0.2	0.1
<b>WW Adjusted Operational Ex A&amp;D</b>	<b>3.4%</b>	<b>3.7%</b>	<b>3.5%</b>
U.S.	4.9%	4.1%	4.6%
International	1.4%	3.3%	2.2%

**Note:** Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measures

(Dollars in Millions Except Per Share Data)	Third Quarter		Nine Months Ended	
	2025	2024	2025	2024
Net Earnings, after tax- as reported	\$5,152	\$2,694	\$21,688	\$10,635
<i>Pre-tax Adjustments</i>				
Litigation related	15	2,388	(6,894)	5,466
Intangible Asset Amortization expense	1,048	1,171	3,435	3,355
COVID-19 Vaccine related costs	-	4	-	77
Restructuring related <sup>1</sup>	168	47	302	207
Medical Device Regulation	-	38	-	157
Acquisition, integration and divestiture related	97	328	475	928
(Gains)/losses on securities	(387)	(37)	(327)	374
IPR&D impairments	-	-	-	194
Other	2	-	29	-
<i>Tax Adjustments</i>				
Tax impact on special item adjustments <sup>2</sup>	(168)	(762)	826	(2,055)
Tax legislation and other tax related	874	5	672	(42)
Adjusted Net Earnings, after tax	<b>\$6,801</b>	<b>\$5,876</b>	<b>\$20,206</b>	<b>\$19,296</b>
Average shares outstanding (Diluted)	2,428.6	2,427.9	2,424.8	2,429.5
Adjusted net earnings per share (Diluted)	<b>\$2.80</b>	<b>\$2.42</b>	<b>\$8.33</b>	<b>\$7.94</b>
Operational adjusted net earnings per share (Diluted)	<b>\$2.72</b>		<b>\$8.24</b>	

Notes:

<sup>1</sup> In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of \$19 million in the fiscal third quarter of 2024 (\$100 million Q3 2024 YTD) included the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.

In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of \$40 million in the fiscal third quarter of 2025 (\$145 million Q3 2025 YTD) and \$28 million in the fiscal third quarter of 2024 (\$107 million Q3 2024 YTD) primarily includes costs related to market and product exits.

In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of \$128 million in the fiscal third quarter of 2025 (\$157 million Q3 2025 YTD) primarily includes costs related to asset impairments and market and product exits.

<sup>2</sup> The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries  
GAAP to Non-GAAP Reconciliation  
\$ in Millions

Quarter to Date

	Third Quarter Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Third Quarter Sept 28, 2025 Non-GAAP
<i>Innovative Medicine</i>									
Cost of products sold	\$ 3,672	(568)	-	-	(11)	-	-	-	3,093
Selling, marketing and admin expenses	2,869	-	-	-	-	-	-	-	2,869
Research and development expense	2,944	-	-	-	-	-	-	-	2,944
Other segment items	(368)	-	5	-	(48)	174	-	(1)	(238)
Adjusted Income Before Tax by Segment	<b>6,446</b>	<b>568</b>	<b>(5)</b>	<b>-</b>	<b>59</b>	<b>(174)</b>	<b>-</b>	<b>1</b>	<b>6,895</b>
<i>MedTech</i>									
Cost of products sold	\$ 3,612	(480)	-	(12)	(1)	-	-	-	3,119
Selling, marketing and admin expenses	2,801	-	-	-	-	-	-	-	2,801
Research and development expense	728	-	-	-	-	-	-	-	728
Other segment items	2	-	5	(156)	(48)	213	-	(1)	15
Adjusted Income Before Tax by Segment	<b>1,287</b>	<b>480</b>	<b>(5)</b>	<b>168</b>	<b>49</b>	<b>(213)</b>	<b>-</b>	<b>1</b>	<b>1,767</b>
<i>Expenses not allocated to segments</i>									
Cost of products sold	\$ 19	-	-	-	-	-	-	-	19
Selling, marketing and admin expenses	252	-	-	-	-	-	-	-	252
Research and development expense	-	-	-	-	-	-	-	-	-
Other segment items	(31)	-	(25)	-	11	-	-	-	(45)
Adjusted Income Before Tax by Segment	<b>(240)</b>	<b>-</b>	<b>25</b>	<b>-</b>	<b>(11)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(226)</b>
<i>Johnson &amp; Johnson Consolidated</i>									
Cost of products sold	\$ 7,303	(1,048)	-	(12)	(12)	-	-	-	6,231
Selling, marketing and admin expenses	5,922	-	-	-	-	-	-	-	5,922
Research and development expense	3,672	-	-	-	-	-	-	-	3,672
Other (Income) / Expense	(478)	-	(15)	(93)	(85)	387	-	(2)	(286)
In-process research and development impairments	-	-	-	-	-	-	-	-	-
Interest (Income)/Expense	18	-	-	-	-	-	-	-	18
Restructuring	63	-	-	(63)	-	-	-	-	-
Adjusted Income Before Tax	<b>7,493</b>	<b>1,048</b>	<b>15</b>	<b>168</b>	<b>97</b>	<b>(387)</b>	<b>-</b>	<b>2</b>	<b>8,436</b>
Provision for taxes on income	2,341	193	3	34	16	(87)	(874)	9	1,635
Net Earnings	<b>5,152</b>	<b>855</b>	<b>12</b>	<b>134</b>	<b>81</b>	<b>(300)</b>	<b>874</b>	<b>(7)</b>	<b>6,801</b>

Johnson & Johnson and Subsidiaries  
GAAP to Non-GAAP Reconciliation  
\$ in Millions

Quarter to Date

	Third Quarter Sept 29, 2024 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Third Quarter Sept 29, 2024 Non-GAAP
<i>Innovative Medicine</i>										
Cost of products sold	\$ 3,549	(695)						(2)		2,852
Selling, marketing and admin expenses	2,491									2,491
Research and development expense	4,213									4,211
Other segment items	(155)							(2)		(495)
Adjusted Income Before Tax by Segment	4,482	695	356	19	(6)	41	-	4	-	5,521
<i>MedTech</i>										
Cost of products sold	\$ 3,381	(476)								2,727
Selling, marketing and admin expenses	2,723									2,720
Research and development expense	739									684
Other segment items	(11)									(141)
Adjusted Income Before Tax by Segment	1,059	476	19	28	(36)	(85)	(4)	38	-	1,901
<i>Expenses not allocated to segments</i>										
Cost of products sold	\$ 33									33
Selling, marketing and admin expenses	264									264
Research and development expense	-									-
Other segment items	1,906									(152)
Adjusted Income Before Tax by Segment	(2,203)	-	2,013	-	(45)	45	-	-	-	(145)
<i>Johnson &amp; Johnson Consolidated</i>										
Cost of products sold	\$ 6,963	(1,171)								5,612
Selling, marketing and admin expenses	5,478									5,475
Research and development expense	4,952									4,895
Other (Income) / Expense	1,798									(689)
In-process research and development impairments	-									-
Interest (Income)/Expense	(99)									(99)
Restructuring	41									-
Adjusted Income Before Tax	3,338	1,171	2,388	47	328	(37)	38	4	-	7,277
Provision for taxes on income	644	169	527	9	59	(9)	6	1	(5)	1,401
Net Earnings	2,694	1,002	1,861	38	269	(28)	32	3	5	5,876

Johnson & Johnson and Subsidiaries  
GAAP to Non-GAAP Reconciliation  
\$ in Millions

Year to Date

	Nine Months Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Nine Months Sept 28, 2025 Non-GAAP
<i>Innovative Medicine</i>									
Cost of products sold	\$ 11,670	(2,002)			(24)				9,644
Selling, marketing and admin expenses	7,919								7,919
Research and development expense	8,361								8,361
Other segment items	(520)		74		(275)	164		(14)	(571)
Adjusted Income Before Tax by Segment	17,208	2,002	(74)	-	299	(164)	-	14	19,285
<i>MedTech</i>									
Cost of products sold	\$ 10,576	(1,433)			(35)	(52)			9,056
Selling, marketing and admin expenses	8,319								8,319
Research and development expense	2,052					37			2,089
Other segment items	132		(78)	(267)	(155)	163		(15)	(220)
Adjusted Income Before Tax by Segment	3,912	1,433	78	302	170	(163)	-	15	5,747
<i>Expenses not allocated to segments</i>									
Cost of products sold	\$ 42								42
Selling, marketing and admin expenses	685								685
Research and development expense									-
Other segment items	(7,222)		6,898		(6)				(330)
Adjusted Income Before Tax by Segment	6,495	-	(6,898)	-	6	-	-	-	(397)
<i>Johnson &amp; Johnson Consolidated</i>									
Cost of products sold	\$ 22,288	(3,435)			(35)	(76)			18,742
Selling, marketing and admin expenses	16,923								16,923
Research and development expense	10,413					37			10,450
Other (Income) / Expense	(7,692)		6,894	(123)	(436)	327		(29)	(1,059)
In-process research and development impairments	-								-
Interest (Income)/Expense	(62)								(62)
Restructuring	144			(144)					-
Adjusted Income Before Tax	27,615	3,435	(6,894)	302	475	(327)	-	29	24,635
Provision for taxes on income	5,927	603	(1,541)	58	118	(73)	(672)	9	4,429
Net Earnings	21,688	2,832	(5,353)	244	357	(254)	672	20	20,206

Johnson & Johnson and Subsidiaries  
GAAP to Non-GAAP Reconciliation  
\$ in Millions

Year to Date

	Nine Months Sept 29, 2024 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Nine Months Sept. 29, 2024 Non-GAAP
<b>Innovative Medicine</b>											
Cost of products sold	\$ 10,522	(2,087)							(8)		8,427
Selling, marketing and admin expenses	7,594										7,594
Research and development expense	9,831										9,812
Other segment items	(225)										(996)
Adjusted Income Before Tax by Segment	14,910	2,087	399	194	100	(54)	26	(26)	77	-	17,795
<b>MedTech</b>											
Cost of products sold	\$ 9,749	(1,268)									8,194
Selling, marketing and admin expenses	7,976										7,964
Research and development expense	2,103										1,955
Other segment items	173			(15)		(92)	(69)	(472)	(48)		(454)
Adjusted Income Before Tax by Segment	3,668	1,268	15	-	107	747	48	157	-	-	6,010
<b>Expenses not allocated to segments</b>											
Cost of products sold	\$ 72										72
Selling, marketing and admin expenses	846										846
Research and development expense											
Other segment items	4,860			(5,052)			(127)	(352)			(671)
Adjusted Income Before Tax by Segment	(5,778)	-	5,052	-		127	352	-	-	-	(247)
<b>Johnson &amp; Johnson Consolidated</b>											
Cost of products sold	\$ 20,343	(3,355)									16,693
Selling, marketing and admin expenses	16,416										16,404
Research and development expense	11,934										11,767
Other (Income) / Expense	4,855										(1,688)
In-process research and development impairments	194										-
Interest (Income)/Expense	(433)										(433)
Restructuring	192										
Adjusted Income Before Tax	12,800	3,355	5,466	194	207	928	374	157	77	-	23,558
Provision for taxes on income	2,165	473	1,224	43	42	222	5	29	17	42	4,262
Net Earnings	10,635	2,882	4,242	151	165	706	369	128	60	(42)	19,296